N-cyclohex-3-en-1-yl-5,6-dimethyl-2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: N-cyclohex-3-en-1-yl-5,6-dimethyl-2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• 化学式: C₂₀H₂₂N₄
• 分子量: 318.4
• InChiKey: SDLLPSMFNIXACN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Compounds specific to adenosine A1 receptors and uses thereof
  申请人：——

  公开号：US20030045536A1

  公开（公告）日：2003-03-06

  This invention pertains to compounds which specifically inhibit the adenosine A 1 receptor and the use of these compounds to treat a disease associated with A 1 adenosine receptors in a subject.

  本发明涉及特异性抑制腺苷A1受体的化合物，以及使用这些化合物治疗与A1腺苷受体相关的疾病的方法。
• Compounds specific to adenosine A, receptors and uses thereof
  申请人：OSI Pharmaceuticals, Inc.

  公开号：US20040082598A1

  公开（公告）日：2004-04-29

  This invention pertains to compounds which specifically inhibit the adenosine A 1 receptor and the use of these compounds to treat a disease associated with A 1 adenosine receptors in a subject.

  本发明涉及特异性抑制腺苷A1受体的化合物，以及使用这些化合物治疗与A1腺苷受体相关的疾病的方法。
• Compounds specific to adenosine A2a receptor and uses thereof
  申请人：——

  公开号：US20030036545A1

  公开（公告）日：2003-02-20

  This invention pertains to compounds which specifically inhibit the adenosine A 2a receptor and the use of these compounds to treat a disease associated with A 2a adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

  本发明涉及特异性抑制腺苷A2a受体的化合物，以及使用这些化合物治疗与A2a腺苷受体有关的疾病的方法，包括向患者投与治疗有效量的这些化合物。
• Pyrrolo [2, 3d] pyrimidine compositions and their use
  申请人：——

  公开号：US20020028782A1

  公开（公告）日：2002-03-07

  Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.

  本发明揭示了一种新型的脱氧腺苷嘌呤类化合物，可用于治疗腺苷受体刺激引起的疾病。
• Compounds specific to adenosine A3 receptor and uses thereof
  申请人：——

  公开号：US20030073708A1

  公开（公告）日：2003-04-17

  This invention pertains to compounds which specifically inhibit the adenosine A 3 receptor and the use of these compounds to treat a disease associated with A 3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.

  本发明涉及特异性抑制腺苷A3受体的化合物，以及使用这些化合物治疗与A3腺苷受体相关的疾病，包括向受体中施加治疗有效量的化合物。